{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T06:36:14Z","timestamp":1780727774745,"version":"3.54.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T00:00:00Z","timestamp":1724976000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T00:00:00Z","timestamp":1724976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s12185-024-03839-4","type":"journal-article","created":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T03:44:04Z","timestamp":1724989444000},"page":"645-650","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A case of posttransplant isolated extramedullary relapse of acute lymphoblastic leukemia achieving durable treatment-free remission with blinatumomab and donor lymphocyte infusion"],"prefix":"10.1007","volume":"120","author":[{"given":"Makoto","family":"Nishijima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1253-6948","authenticated-orcid":false,"given":"Kentaro","family":"Ido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Okayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Okamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatomo","family":"Kuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Makuuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsutaka","family":"Nishimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Nakamae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Hino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohisa","family":"Nakamae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,30]]},"reference":[{"key":"3839_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.7326\/M19-2936","volume":"172","author":"GB McDonald","year":"2020","unstructured":"McDonald GB, Sandmaier BM, Mielcarek M, Sorror M, Pergam SA, Cheng GS, et al. Survival, nonrelapse mortality, and relapse-related mortality after allogeneic hematopoietic cell transplantation: comparing 2003\u20132007 versus 2013\u20132017 cohorts. Ann Intern Med. 2020;172:229\u201339.","journal-title":"Ann Intern Med"},{"key":"3839_CR2","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.jtct.2023.07.015","volume":"29","author":"MB Abid","year":"2023","unstructured":"Abid MB, Estrada-Merly N, Zhang MJ, Chen K, Bredeson C, Allan D, et al. Younger matched unrelated donors confer decreased relapse risk compared to older sibling donors in older patients with B cell acute lymphoblastic leukemia undergoing allogeneic hematopoietic cell transplantation. Transpl Cell Ther. 2023;29:611\u20138.","journal-title":"Transpl Cell Ther"},{"key":"3839_CR3","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1038\/s41409-023-01989-3","volume":"58","author":"Y Gao","year":"2023","unstructured":"Gao Y, Wu H, Shi Z, Gao F, Shi J, Luo Y, et al. Prognostic factors and clinical outcomes in patients with relapsed acute leukemia after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transpl. 2023;58:863\u201373.","journal-title":"Bone Marrow Transpl"},{"key":"3839_CR4","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/ejh.13947","volume":"110","author":"C Ferra Coll","year":"2023","unstructured":"Ferra Coll C, de la Morgades Fe M, Prieto Garcia L, Vaz CP, Heras Fernando MI, Bailen Almorox R, et al. Prognosis of patients with acute lymphoblastic leukaemia relapsing after allogeneic stem cell transplantation. Eur J Haematol. 2023;110:659\u201368.","journal-title":"Eur J Haematol"},{"key":"3839_CR5","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00277-020-04310-0","volume":"100","author":"Y Mori","year":"2021","unstructured":"Mori Y, Sasaki K, Ito Y, Kuriyama T, Ueno T, Kadowaki M, et al. Outcome predictors after retransplantation in relapsed acute lymphoblastic leukemia: a multicenter, retrospective study. Ann Hematol. 2021;100:197\u2013208.","journal-title":"Ann Hematol"},{"key":"3839_CR6","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1111\/bjh.15973","volume":"186","author":"A Nagler","year":"2019","unstructured":"Nagler A, Labopin M, Dholaria B, Finke J, Brecht A, Schanz U, et al. Second allogeneic stem cell transplantation in patients with acute lymphoblastic leukaemia: a study on behalf of the acute leukaemia working party of the european society for blood and marrow transplantation. Br J Haematol. 2019;186:767\u201376.","journal-title":"Br J Haematol"},{"key":"3839_CR7","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.clml.2022.12.011","volume":"23","author":"A Pinchinat","year":"2023","unstructured":"Pinchinat A, Gupta S, Cooper SL, Rau RE. SOHO state of the art updates and next questions | optimal timing of blinatumomab for the treatment of B-acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2023;23:159\u201367.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"3839_CR8","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1016\/j.bbmt.2019.04.010","volume":"25","author":"AS Stein","year":"2019","unstructured":"Stein AS, Kantarjian H, Gokbuget N, Bargou R, Litzow MR, Rambaldi A, et al. Blinatumomab for acute lymphoblastic leukemia relapse after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transpl. 2019;25:1498\u2013504.","journal-title":"Biol Blood Marrow Transpl"},{"key":"3839_CR9","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"Kantarjian H, Stein A, Gokbuget N, Fielding AK, Schuh AC, Ribera JM, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376:836\u201347.","journal-title":"N Engl J Med"},{"key":"3839_CR10","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s00277-018-3495-2","volume":"98","author":"SH Jung","year":"2019","unstructured":"Jung SH, Lee SR, Yang DH, Lee S, Yoon JH, Lee H, et al. Efficacy and safety of blinatumomab treatment in adult Korean patients with relapsed\/refractory acute lymphoblastic leukemia on behalf of the Korean Society of Hematology All Working Party. Ann Hematol. 2019;98:151\u20138.","journal-title":"Ann Hematol"},{"key":"3839_CR11","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1002\/ajh.24783","volume":"92","author":"I Aldoss","year":"2017","unstructured":"Aldoss I, Song J, Stiller T, Nguyen T, Palmer J, O\u2019Donnell M, et al. Correlates of resistance and relapse during blinatumomab therapy for relapsed\/refractory acute lymphoblastic leukemia. Am J Hematol. 2017;92:858\u201365.","journal-title":"Am J Hematol"},{"key":"3839_CR12","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.bbmt.2017.02.012","volume":"23","author":"T Miyamoto","year":"2017","unstructured":"Miyamoto T, Fukuda T, Nakashima M, Henzan T, Kusakabe S, Kobayashi N, et al. Donor lymphocyte infusion for relapsed hematological malignancies after unrelated allogeneic bone marrow transplantation facilitated by the Japan marrow donor program. Biol Blood Marrow Transpl. 2017;23:938\u201344.","journal-title":"Biol Blood Marrow Transpl"},{"key":"3839_CR13","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1001\/jamaoncol.2018.2091","volume":"4","author":"MA Kharfan-Dabaja","year":"2018","unstructured":"Kharfan-Dabaja MA, Labopin M, Polge E, Nishihori T, Bazarbachi A, Finke J, et al. Association of second allogeneic hematopoietic cell transplant vs donor lymphocyte infusion with overall survival in patients with acute myeloid leukemia relapse. JAMA Oncol. 2018;4:1245\u201353.","journal-title":"JAMA Oncol"},{"key":"3839_CR14","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.exphem.2018.03.002","volume":"62","author":"G Orti","year":"2018","unstructured":"Orti G, Sanz J, Garcia-Cadenas I, Sanchez-Ortega I, Alonso L, Jimenez MJ, et al. Analysis of relapse after transplantation in acute leukemia: a comparative on second allogeneic hematopoietic cell transplantation and donor lymphocyte infusions. Exp Hematol. 2018;62:24\u201332.","journal-title":"Exp Hematol"},{"key":"3839_CR15","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41409-022-01846-9","volume":"58","author":"P Chauvet","year":"2023","unstructured":"Chauvet P, Paviglianiti A, Labopin M, Labussiere H, Boissel N, Robin M, et al. Combining blinatumomab and donor lymphocyte infusion in B-ALL patients relapsing after allogeneic hematopoietic cell transplantation: a study of the SFGM-TC. Bone Marrow Transpl. 2023;58:72\u20139.","journal-title":"Bone Marrow Transpl"},{"key":"3839_CR16","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s12185-021-03228-1","volume":"115","author":"H Nakamae","year":"2022","unstructured":"Nakamae H, Nakane T, Okamura H, Koh H, Nakashima Y, Hirose A, et al. A phase II study of post-transplant cyclophosphamide combined with tacrolimus for GVHD prophylaxis after HLA-matched related\/unrelated allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2022;115:77\u201386.","journal-title":"Int J Hematol"},{"key":"3839_CR17","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s12185-021-03231-6","volume":"115","author":"SH Lee","year":"2022","unstructured":"Lee SH, Yoon JH, Min GJ, Park SS, Park S, Lee SE, et al. Response to blinatumomab or inotuzumab ozogamicin for isolated extramedullary relapse of adult acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation: a case study. Int J Hematol. 2022;115:135\u20139.","journal-title":"Int J Hematol"},{"key":"3839_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-019-0708-9","author":"SY Yoon","year":"2020","unstructured":"Yoon SY, Yoon JH, Min GJ, Park SS, Park S, Lee SE, et al. Experience of blinatumomab salvage for patients with acute lymphoblastic leukemia presenting with isolated extramedullary relapse after previous allogeneic hematopoietic cell transplantation. Bone Marrow Transpl. 2020;55:1469\u201372. https:\/\/doi.org\/10.1038\/s41409-019-0708-9.","journal-title":"Bone Marrow Transpl"},{"issue":"859","key":"3839_CR19","first-page":"e1","volume":"27","author":"V Hazar","year":"2021","unstructured":"Hazar V, Ozturk G, Yalcin K, Uygun V, Aksoylar S, Kupesiz A, et al. Different kinetics and risk factors for isolated extramedullary relapse after allogeneic hematopoietic stem cell transplantation in children with acute leukemia. Transpl Cell Ther. 2021;27(859):e1\u201310.","journal-title":"Transpl Cell Ther"},{"key":"3839_CR20","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/j.bbmt.2017.03.023","volume":"23","author":"N Shem-Tov","year":"2017","unstructured":"Shem-Tov N, Saraceni F, Danylesko I, Shouval R, Yerushalmi R, Nagler A, et al. Isolated extramedullary relapse of acute leukemia after allogeneic stem cell transplantation: different kinetics and better prognosis than systemic relapse. Biol Blood Marrow Transpl. 2017;23:1087\u201394.","journal-title":"Biol Blood Marrow Transpl"},{"key":"3839_CR21","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1038\/s41375-020-01089-x","volume":"35","author":"AH Wei","year":"2021","unstructured":"Wei AH, Ribera JM, Larson RA, Ritchie D, Ghobadi A, Chen Y, et al. Biomarkers associated with blinatumomab outcomes in acute lymphoblastic leukemia. Leukemia. 2021;35:2220\u201331.","journal-title":"Leukemia"},{"key":"3839_CR22","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1182\/blood.2020006287","volume":"137","author":"Y Zhao","year":"2021","unstructured":"Zhao Y, Aldoss I, Qu C, Crawford JC, Gu Z, Allen EK, et al. Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL. Blood. 2021;137:471\u201384.","journal-title":"Blood"},{"key":"3839_CR23","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1159\/000531834","volume":"16","author":"J Mori","year":"2023","unstructured":"Mori J, Shingai N, Kobayashi T, Doki N. Combination of donor lymphocyte infusion and blinatumomab for B-cell lymphoblastic lymphoma relapse after allogeneic stem-cell transplantation. Case Rep Oncol. 2023;16:640\u20134.","journal-title":"Case Rep Oncol"},{"key":"3839_CR24","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1038\/bmt.2016.104","volume":"51","author":"M Ueda","year":"2016","unstructured":"Ueda M, de Lima M, Caimi P, Tomlinson B, Little J, Creger R, et al. Concurrent blinatumomab and donor lymphocyte infusions for treatment of relapsed pre-B-cell ALL after allogeneic hematopoietic cell transplant. Bone Marrow Transpl. 2016;51:1253\u20135.","journal-title":"Bone Marrow Transpl"},{"issue":"20","key":"3839_CR25","first-page":"e1","volume":"28","author":"K Ido","year":"2022","unstructured":"Ido K, Koh H, Hirose A, Seto T, Makuuchi Y, Kuno M, et al. Effect of donor NKG2D polymorphism on relapse after haploidentical transplantation with post-transplantation cyclophosphamide. Transpl Cell Ther. 2022;28(20):e1\u201310.","journal-title":"Transpl Cell Ther"},{"key":"3839_CR26","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1182\/bloodadvances.2018027003","volume":"3","author":"M Yeshurun","year":"2019","unstructured":"Yeshurun M, Weisdorf D, Rowe JM, Tallman MS, Zhang MJ, Wang HL, et al. The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia. Blood Adv. 2019;3:670\u201380.","journal-title":"Blood Adv"},{"key":"3839_CR27","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1038\/leu.2014.145","volume":"28","author":"M Stern","year":"2014","unstructured":"Stern M, de Wreede LC, Brand R, van Biezen A, Dreger P, Mohty M, et al. Sensitivity of hematological malignancies to graft-versus-host effects: an EBMT megafile analysis. Leukemia. 2014;28:2235\u201340.","journal-title":"Leukemia"},{"key":"3839_CR28","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1182\/blood.2020007311","volume":"137","author":"JM Ribera","year":"2021","unstructured":"Ribera JM, Morgades M, Ciudad J, Montesinos P, Esteve J, Genesc\u00e0 E, et al. Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome-negative adult lymphoblastic leukemia. Blood. 2021;137:1879\u201394.","journal-title":"Blood"},{"key":"3839_CR29","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1111\/bjh.19104","volume":"203","author":"D Ocadlikova","year":"2023","unstructured":"Ocadlikova D, Lussana F, Fracchiolla N, Bonifacio M, Santoro L, Delia M, et al. Blinatumomab differentially modulates peripheral blood and bone marrow immune cell repertoire: A Campus ALL study. Br J Haematol. 2023;203:637\u201350.","journal-title":"Br J Haematol"},{"key":"3839_CR30","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1182\/blood-2015-06-649111","volume":"126","author":"G Zugmaier","year":"2015","unstructured":"Zugmaier G, Gokbuget N, Klinger M, Viardot A, Stelljes M, Neumann S, et al. Long-term survival and T-cell kinetics in relapsed\/refractory ALL patients who achieved MRD response after blinatumomab treatment. Blood. 2015;126:2578\u201384.","journal-title":"Blood"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-024-03839-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-024-03839-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-024-03839-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T08:44:53Z","timestamp":1730105093000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-024-03839-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,30]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["3839"],"URL":"https:\/\/doi.org\/10.1007\/s12185-024-03839-4","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,30]]},"assertion":[{"value":"26 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The potential conflicts of interest for each author are as follows: YO received honoraria from Sanofi K.K. HO received research funding from Takeda Pharmaceutical Company Limited and honoraria from Asahi Kasei Pharma Corporation and Nippon Shinyaku Co., Ltd. MK received research funding from Shionogi & Co. Ltd. YM received honoraria from Asahi Kasei Pharma Corporation. MNishimoto received research funding from Astellas Pharma Inc. and Pfizer Japan Inc., and honoraria from Asahi Kasei Pharma Corporation, Astellas Pharma Inc., Nippon Shinyaku Co., Ltd., and Takeda Pharmaceutical Company Limited. YN received research funding from Amgen Inc. and Astellas Pharma Inc., and honoraria from Amgen Inc. and Astellas Pharma Inc. HK received research funding from Amgen Inc., Takeda Pharmaceutical Company Limited, and honoraria from Asahi Kasei Pharma Corporation. MNakamae received honoraria as the spouse of HN (please refer to HN). MH received research funding from Nippon Shinyaku Co., Ltd., scholarship grants from Asahi Kasei Pharma Corporation, Nippon Kayaku Co., Ltd., Takeda Pharmaceutical Company Limited, and honoraria from Amgen Inc., Asahi Kasei Pharma Corporation, Astellas Pharma Inc., Eisai Co., Ltd., Nippon Kayaku Co., Ltd., Nippon Shinyaku Co., Ltd., Pfizer Japan Inc., Sanofi K.K., and Takeda Pharmaceutical Company Limited. HN received research funding from Astellas Pharma Inc., Takeda Pharmaceutical Company Limited and honoraria from Amgen Inc., Astellas Pharma Inc., Nippon Shinyaku Co., Ltd., Sanofi K.K., and Takeda Pharmaceutical Company Limited. This report was not funded by any of these companies. The other authors declare no conflicts of interest in association with the present report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}